Safety and Effectiveness of Once-Daily Tadalafil (5 mg) Therapy in Korean Men with Benign Prostatic Hyperplasia/Lower Urinary Tract Symptoms in a Real-World Clinical Setting: Results from a Post- Marketing Surveillance Study
Purpose: The aim of this study was to investigate the safety and effectiveness of tadalafil 5 mg once daily (quaque die [everyday], QD) among Korean men with benign prostatic hyperplasia (BPH)/lower urinary tract symptoms (LUTS) in a real-world clinical setting. Materials and Methods: This was a s...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Korean Society for Sexual Medicine and Andrology
2018-05-01
|
Series: | The World Journal of Men's Health |
Subjects: | |
Online Access: | https://www.wjmh.org/Synapse/Data/PDFData/2074WJMH/wjmh-36-161.pdf |
id |
doaj-0ca7422b3218487d99f90950b8c8d815 |
---|---|
record_format |
Article |
spelling |
doaj-0ca7422b3218487d99f90950b8c8d8152020-11-24T22:45:51ZengKorean Society for Sexual Medicine and AndrologyThe World Journal of Men's Health2287-42082287-46902018-05-0136216117010.5534/wjmh.17017Safety and Effectiveness of Once-Daily Tadalafil (5 mg) Therapy in Korean Men with Benign Prostatic Hyperplasia/Lower Urinary Tract Symptoms in a Real-World Clinical Setting: Results from a Post- Marketing Surveillance StudyJi Eon Won0Ji Yeon Chu1Hyunah Caroline Choi2Yun Chen3Hyun Jun Park4Héctor José Dueñas5Lilly KoreaLilly KoreaLilly KoreaLilly Suzhou Pharmaceutical CompanyPusan National University School of MedicineEli Lilly de MexicoPurpose: The aim of this study was to investigate the safety and effectiveness of tadalafil 5 mg once daily (quaque die [everyday], QD) among Korean men with benign prostatic hyperplasia (BPH)/lower urinary tract symptoms (LUTS) in a real-world clinical setting. Materials and Methods: This was a single-country, prospective, observational cohort study in which patients newly prescribed tadalafil 5 mg QD for the treatment of BPH/LUTS were followed-up for 12±2 or 24±2 weeks, or to the last treatment, during post-marketing surveillance. Safety was evaluated in terms of the frequency of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs). Effectiveness was assessed by changes in the International Prostate Symptom Score (IPSS) from baseline to each endpoint. Results: All patients receiving ≥1 dose of tadalafil 5 mg QD (N=637) were included in the safety population. Two percent of patients (n=13) experienced 15 TEAEs of mild (n=10; 66.7%) or moderate (n=5; 33.3%) severity. No severe TEAEs and no SAEs were reported. Effectiveness evaluations included all patients receiving tadalafil who had both baseline and endpoint observations (12-week, N=265; 24-week, N=44). Compared with baseline, the mean IPSS total score (±standard error) significantly improved by 4.7±0.3 and 6.4±0.7 points at the 12- and 24-week endpoints, respectively (p<0.0001), with significant improvements also observed on the storage, voiding, and quality of life subscores. In total, 69.1% of the patients had a clinically meaningful ≥3-point improvement in the IPSS total score. Conclusions: Tadalafil 5 mg QD was well tolerated and effective in Korean men with BPH/LUTS in a real-world clinical setting.https://www.wjmh.org/Synapse/Data/PDFData/2074WJMH/wjmh-36-161.pdfLower urinary tract symptomsPhosphodiesterase 5 InhibitorsProstatic hyperplasiaSafetyTadalafil |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Ji Eon Won Ji Yeon Chu Hyunah Caroline Choi Yun Chen Hyun Jun Park Héctor José Dueñas |
spellingShingle |
Ji Eon Won Ji Yeon Chu Hyunah Caroline Choi Yun Chen Hyun Jun Park Héctor José Dueñas Safety and Effectiveness of Once-Daily Tadalafil (5 mg) Therapy in Korean Men with Benign Prostatic Hyperplasia/Lower Urinary Tract Symptoms in a Real-World Clinical Setting: Results from a Post- Marketing Surveillance Study The World Journal of Men's Health Lower urinary tract symptoms Phosphodiesterase 5 Inhibitors Prostatic hyperplasia Safety Tadalafil |
author_facet |
Ji Eon Won Ji Yeon Chu Hyunah Caroline Choi Yun Chen Hyun Jun Park Héctor José Dueñas |
author_sort |
Ji Eon Won |
title |
Safety and Effectiveness of Once-Daily Tadalafil (5 mg) Therapy in Korean Men with Benign Prostatic Hyperplasia/Lower Urinary Tract Symptoms in a Real-World Clinical Setting: Results from a Post- Marketing Surveillance Study |
title_short |
Safety and Effectiveness of Once-Daily Tadalafil (5 mg) Therapy in Korean Men with Benign Prostatic Hyperplasia/Lower Urinary Tract Symptoms in a Real-World Clinical Setting: Results from a Post- Marketing Surveillance Study |
title_full |
Safety and Effectiveness of Once-Daily Tadalafil (5 mg) Therapy in Korean Men with Benign Prostatic Hyperplasia/Lower Urinary Tract Symptoms in a Real-World Clinical Setting: Results from a Post- Marketing Surveillance Study |
title_fullStr |
Safety and Effectiveness of Once-Daily Tadalafil (5 mg) Therapy in Korean Men with Benign Prostatic Hyperplasia/Lower Urinary Tract Symptoms in a Real-World Clinical Setting: Results from a Post- Marketing Surveillance Study |
title_full_unstemmed |
Safety and Effectiveness of Once-Daily Tadalafil (5 mg) Therapy in Korean Men with Benign Prostatic Hyperplasia/Lower Urinary Tract Symptoms in a Real-World Clinical Setting: Results from a Post- Marketing Surveillance Study |
title_sort |
safety and effectiveness of once-daily tadalafil (5 mg) therapy in korean men with benign prostatic hyperplasia/lower urinary tract symptoms in a real-world clinical setting: results from a post- marketing surveillance study |
publisher |
Korean Society for Sexual Medicine and Andrology |
series |
The World Journal of Men's Health |
issn |
2287-4208 2287-4690 |
publishDate |
2018-05-01 |
description |
Purpose: The aim of this study was to investigate the safety and effectiveness of tadalafil 5 mg once daily (quaque die [everyday], QD)
among Korean men with benign prostatic hyperplasia (BPH)/lower urinary tract symptoms (LUTS) in a real-world clinical setting.
Materials and Methods: This was a single-country, prospective, observational cohort study in which patients newly prescribed
tadalafil 5 mg QD for the treatment of BPH/LUTS were followed-up for 12±2 or 24±2 weeks, or to the last treatment,
during post-marketing surveillance. Safety was evaluated in terms of the frequency of treatment-emergent adverse events
(TEAEs) and serious adverse events (SAEs). Effectiveness was assessed by changes in the International Prostate Symptom Score
(IPSS) from baseline to each endpoint.
Results: All patients receiving ≥1 dose of tadalafil 5 mg QD (N=637) were included in the safety population. Two percent
of patients (n=13) experienced 15 TEAEs of mild (n=10; 66.7%) or moderate (n=5; 33.3%) severity. No severe TEAEs and no
SAEs were reported. Effectiveness evaluations included all patients receiving tadalafil who had both baseline and endpoint
observations (12-week, N=265; 24-week, N=44). Compared with baseline, the mean IPSS total score (±standard error) significantly
improved by 4.7±0.3 and 6.4±0.7 points at the 12- and 24-week endpoints, respectively (p<0.0001), with significant
improvements also observed on the storage, voiding, and quality of life subscores. In total, 69.1% of the patients had a clinically
meaningful ≥3-point improvement in the IPSS total score.
Conclusions: Tadalafil 5 mg QD was well tolerated and effective in Korean men with BPH/LUTS in a real-world clinical setting. |
topic |
Lower urinary tract symptoms Phosphodiesterase 5 Inhibitors Prostatic hyperplasia Safety Tadalafil |
url |
https://www.wjmh.org/Synapse/Data/PDFData/2074WJMH/wjmh-36-161.pdf |
work_keys_str_mv |
AT jieonwon safetyandeffectivenessofoncedailytadalafil5mgtherapyinkoreanmenwithbenignprostatichyperplasialowerurinarytractsymptomsinarealworldclinicalsettingresultsfromapostmarketingsurveillancestudy AT jiyeonchu safetyandeffectivenessofoncedailytadalafil5mgtherapyinkoreanmenwithbenignprostatichyperplasialowerurinarytractsymptomsinarealworldclinicalsettingresultsfromapostmarketingsurveillancestudy AT hyunahcarolinechoi safetyandeffectivenessofoncedailytadalafil5mgtherapyinkoreanmenwithbenignprostatichyperplasialowerurinarytractsymptomsinarealworldclinicalsettingresultsfromapostmarketingsurveillancestudy AT yunchen safetyandeffectivenessofoncedailytadalafil5mgtherapyinkoreanmenwithbenignprostatichyperplasialowerurinarytractsymptomsinarealworldclinicalsettingresultsfromapostmarketingsurveillancestudy AT hyunjunpark safetyandeffectivenessofoncedailytadalafil5mgtherapyinkoreanmenwithbenignprostatichyperplasialowerurinarytractsymptomsinarealworldclinicalsettingresultsfromapostmarketingsurveillancestudy AT hectorjoseduenas safetyandeffectivenessofoncedailytadalafil5mgtherapyinkoreanmenwithbenignprostatichyperplasialowerurinarytractsymptomsinarealworldclinicalsettingresultsfromapostmarketingsurveillancestudy |
_version_ |
1725687241797271552 |